Article

FDA Recalls Hypertension Drug Irbesartan

The recalls and returns will be managed by the respective distributors separately, according to a press release from the company.

Officials with ScieGen Pharmaceuticals, Inc. are voluntarily recalling listed lots, within expiry, of a type of hypertension medication known as Irbesartan Tablets, USP 75 mg, 150 mg, and 300 mg dosage forms to the consumer level due to an impurity.

The impurity, N-nitrosodiethylamine (NDEA) contained in the API Irbesartan, USP manufactured by Aurobindo Pharma Limited, "is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes," according ot a statement from ScieGen Pharmaceuticals, but "has been classified as a 'probable human carcinogen as per International Agency for Research on Cancer (IARC)'."

To date, Sciegen Pharmaceuticals Inc has not received any reports of adverse events related to this product.

The recalls and returns will be managed by the respective distributors separately, according to a press release from the company.

Related Videos
Pharmacist assisting a patient with pericarditis -- Image credit: Yuri Arcurs/peopleimages.com | stock.adobe.com
Patient receiving diabetes consultation -- Image credit: Syda Productions | stock.adobe.com
California Wildfires, Pharmacies, Community | image Credit: J Bettencourt/peopleimages.com | stock.adobe.com
California Wildfire, Pharmacy, Community | Image Credit: Erin | stock.adobe.com
Allergies, Asthma, Biologic Treatment, Pharmacists | Image Credit: Pixel-Shot | stock.adobe.com
Woman professional nutritionist checking dietary supplements in hand, surrounded by a variety of fruits, nuts, vegetables, and dietary supplements on the table - Image credit: amenic181 | stock.adobe.com